Where Will FSD Pharma Inc (HUGE) Stock Go Next After It Is Higher By 28.44% in a Week?

Overall market sentiment has been high on FSD Pharma Inc (HUGE) stock lately. HUGE receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

FSD Pharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on HUGE!

See Full HUGE Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With HUGE Stock Today?

FSD Pharma Inc (HUGE) stock is trading at $1.40 as of 12:30 PM on Tuesday, Nov 21, an increase of $0.13, or 10.24% from the previous closing price of $1.27. The stock has traded between $1.25 and $1.42 so far today. Volume today is high. So far 455,613 shares have traded compared to average volume of 64,309 shares. To screen for more stocks like FSD Pharma Inc click here.

More About FSD Pharma Inc

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting multiple sclerosis, LUCID-PSYCH, a psychoactive molecule targeting major depressive disorder, and FSD-PEA, an ultra-micronized palmitoyl ethylamine with a favorable safety profile targeting inflammation. Click Here to get the full Stock Report for FSD Pharma Inc stock.